Siggy raises $6 million for AI that checks on therapy patients daily

A mental health startup with a track record, not just an app

Siggy, a New York startup, announced $6 million in pre-seed funding on November 5, 2026, led by Village Global. It is the company's first outside financing, according to the announcement and a separate report from Runtime Wire. The backers are notable mostly for who they bet on before: Mercury CEO Immad Akhund, Cityblock Health's Toyin Ajayi, and Thirty Madison co-founders Steven Gutentag and Demetri Karagas are among the investors, several of whom backed the same founders at earlier companies.

Co-founder and CEO Jonathan Sabbagh built Journey Clinical, a network the company describes as the largest psychedelic-assisted therapy provider in the US. Co-founder Edvard Engesaeth, now Siggy's chief operating officer, co-founded Nurx, the telehealth company that scaled past two million patients. Both have already built insurance-covered care outside the standard doctor's visit once before. "Our mission is to end the mental health crisis, and treatment only works if people stay in it," Sabbagh said in announcing the round.

What the AI actually does, and does not do

Patients start with a free, anonymous chat, no account needed. From there, Siggy uses a one-minute daily check-in on sleep, mood, medication and physical symptoms to build what it calls the Siggy Score, a number both patient and clinician see. Wearable data from Apple Watch, with Oura and Whoop support coming, feeds into the same score.

The company is explicit about the boundary: the AI does not diagnose or prescribe. A licensed clinician makes every treatment call, and Siggy says weekly reviews during a patient's first two months are built in specifically to catch medication side effects or the need for a dosage change, the kind of adjustment that's easy to miss between infrequent prescriber visits. Siggy told Runtime Wire it began building the product in late 2025 and already has paying patients ahead of a public launch.

The dropout problem this is actually chasing

The pitch rests on a real and well-documented gap. Siggy cites SAMHSA figures showing more than 54 million US adults had a mental illness last year, and nearly half got no treatment. It also points to a 2025 HRSA workforce brief estimating that 137 million Americans live in designated mental health professional shortage areas, where only about 27% of need is met. Siggy says it is accepted by most plans in all 50 states, including Blue Cross Blue Shield, Aetna, UnitedHealthcare and Humana, reaching roughly 80% of insured Americans, plus HSA and FSA payment and free access for veterans. Those coverage numbers come from the company itself, not an independent audit.

Treatment dropout is a theme our mental wellbeing coverage keeps circling back to. It's also the problem behind Outro Health's $7 million round for safe antidepressant tapering. Both companies are circling the same structural issue: psychiatric medication management runs on quarterly check-ins, and a lot can go wrong in between.

It's not the only AI sitting between therapy sessions

Siggy is entering a space that already has competitors doing something similar. Wysa and Ash offer CBT-style chat and check-ins without a prescribing clinician attached. MindBridge pairs daily check-ins with a therapist who can read and comment on them, closer to Siggy's model. What's actually new here is less the AI than the plumbing behind it: insurance billing, a prescribing clinician network, and a tapering protocol built into the product from day one, rather than bolted onto an existing chatbot.

What the research on AI check-ins actually shows

The evidence is real, but it doesn't yet support the broad claim that an AI check-in tool will keep people in treatment. A 2024 meta-analysis of 176 randomized trials in World Psychiatry found modest overall benefit from mental health apps (effect size g=0.28 for depression, g=0.26 for anxiety), rising to g=0.38 for apps built specifically for depression. A smaller subset using actual chatbot technology, only about 5% of the apps studied, showed a stronger effect for depression (g=0.53) but a weaker one for anxiety (g=0.18).

A separate 2024 review of 18 trials of CBT-scripted chatbots found the benefit faded by the three-month mark. The most striking result so far comes from a 2025 Dartmouth trial of a generative AI chatbot called Therabot, which found large effects on depression and anxiety that grew rather than shrank over eight weeks. But that's one trial, not yet replicated, and its authors were explicit that no generative AI agent is ready to run mental health care on its own.

Siggy isn't making its AI the therapist, which is the more defensible design choice given that evidence. But none of the research above was run on Siggy's own product, and a company's retention numbers before a public launch aren't proof that the Siggy Score keeps anyone in care longer than they would have stayed otherwise.

Our take

The founders have done this before, and the clinician-in-the-loop model is the more credible version of AI mental health care right now, not the version where a chatbot plays therapist. But $6 million buys an early bet, not evidence. Daily check-ins between appointments are a sound idea with real literature behind the concept, while Siggy's own claims about dropout and coverage remain unverified by anyone outside the company. Ask your own clinician, if you try something like this, what actually happens to the data and whether it changes your care.

Health Trend Wire holds no position in Siggy and was not paid for this article. This is general information, not medical or financial advice.